FDA Black Box Warning HRT 2026: What Changed, What Still Applies, and What It Means for You

Did the FDA really remove the black box warning on HRT?

Yes — but the honest word is "partly." In February 2026, the FDA approved updated labels for the first six menopausal hormone therapy products, removing boxed-warning language about cardiovascular disease, breast cancer, and probable dementia. One boxed warning still remains. This was a labeling update for FDA-approved products, not a blanket statement that HRT is right for everyone.

First, a quick definition. A "black box warning" (the FDA calls it a boxed warning) is the agency's strongest safety alert. It sits in a black-bordered box at the very top of a drug's label, reserved for the most serious risks. Since 2003, that box on menopause hormone products listed risks like cancer, stroke, and blood clots. For more than twenty years, it was the first thing a doctor or patient saw.

So the change is real, and it's big. But it happened in two steps, and the dates matter when you're reading older articles.

One number tells you why officials pushed for this. According to the FDA, in 2020 about 41 million U.S. women were ages 45–64 — squarely in the menopause years — yet only about 2 million received a hormone-therapy prescription. The agency's view is that the old warning scared off a lot of women who could have safely benefited.

What exactly did the FDA remove — and what's the catch?

The FDA removed three risk statements from the boxed warning: cardiovascular disease, breast cancer, and probable dementia. But "removed from the box" does not mean "erased from the label." On the real labels, the heart and clot risks moved into other safety sections, the breast cancer language stayed, and the dementia information still appears further down. The risk format changed dramatically; most of the risk information did not disappear.

Here's what we actually found. We pulled up the updated FDA label for Cenestin (a systemic estrogen pill) — revised 2/2026 — and read what changed. In plain English:

• The boxed warning now reads only: "Endometrial cancer with unopposed estrogen in women with a uterus." The big, scary box got a lot smaller.
• The label's own "Recent Major Changes" note confirms the cardiovascular, breast cancer, and probable-dementia statements were removed from the box in 2/2026.
• Here's the catch. Those risks didn't all disappear. On the Cenestin label, the heart-related risks — blood clots in the legs or lungs (DVT and PE) and stroke — still appear in both the Contraindications section and the Warnings & Precautions section. Breast cancer is still listed under Contraindications too. The probable dementia statement was removed from the box and from Warnings & Precautions — but information about dementia still appears in Geriatric Use and Clinical Studies sections.

So the format changed. The risk information mostly moved sections. That's the truth, and it matters.

What changed, in one table

This is our verified breakdown from the Cenestin 2/2026 label. You won't find this "removed vs. moved vs. still-on-the-label" view on the official summary pages.

To put real numbers on that retained warning: the Cenestin label states the risk of endometrial cancer from estrogen used alone in women with a uterus is roughly 2 to 12 times higher than in non-users, climbing to a 15- to 24-fold increase with five to ten or more years of use. That's exactly why this one stayed in the box.

What warning is still on HRT in 2026?

The boxed warning about endometrial cancer stayed. It applies to systemic estrogen-alone products (whole-body estrogen taken without a second hormone) in women who still have a uterus. The reason is simple biology: estrogen on its own can thicken the lining of the uterus over time, which raises the risk of cancer there.

Let's define the terms, because they drive the whole risk picture:

• Endometrial cancer = cancer of the endometrium, the lining of the uterus.
• Systemic estrogen = estrogen that travels through your whole body (a pill, patch, or gel), as opposed to a local product that mostly works in one area.
• "Unopposed" estrogen = estrogen taken alone, without a progestogen to balance it.
• Progestogen = a second hormone — natural progesterone or a similar drug — that helps protect the uterine lining.

If you have a uterus and take systemic estrogen

This warning is for you, and it didn't change. This is exactly why clinicians usually pair systemic estrogen with a progestogen when a woman still has her uterus. Adding the progestogen has been shown to lower the risk of the lining building up. It doesn't erase every risk — but it's the standard protection, and the FDA kept the warning specifically so this conversation keeps happening.

If you've had a hysterectomy

If your uterus was removed, you don't have a uterine lining to protect, so estrogen-alone is a different conversation — and this particular warning is less relevant to you. Your fit for HRT still depends on your full health history.

Does the FDA warning change mean HRT is safe now?

No. It means the FDA decided the old warning was too broad and not specific enough — not that HRT became safe for everyone. Major medical groups supported updating the label while stressing that the decision still has to be individual. Your age, how long it's been since menopause, the type and dose, your route (pill vs. patch vs. cream), and your personal history all still matter.

The American Cancer Society put it plainly after the change: removing the black box warning does not mean the earlier research was wrong, and it does not mean HRT is now safe for everyone — products can still carry real risks.

The Menopause Society, the leading group of menopause specialists, agreed with the FDA's move but added a careful note: systemic estrogen still comes with potential risks that should be reviewed one-on-one. In their framing, risks tend to be lower for younger, healthy women starting close to the menopause transition, and higher when started in older women or many years after menopause.

Who the conversation often favors

The updated labels now point to timing. Per the FDA, women who start hormone therapy within 10 years of menopause, generally before age 60, tend to have a better balance of benefits and risks — and randomized studies link that timing to lower overall death and fracture rates. That's not a promise about any one person. It's a reason the timing question is now front and center.

Who needs extra caution or a specialist

Stronger caution generally applies if you have a personal history of breast cancer or another hormone-sensitive cancer, blood clots, stroke, heart attack, active liver disease, complex heart risk, or any unexplained vaginal bleeding — or if you'd be starting many years past menopause. None of these is a casual checkbox. They're reasons to talk to a clinician who knows your history.

What we won't tell you

• ❌ "HRT is safe for everyone now." (It isn't.)
• ❌ "The FDA proved HRT prevents dementia." (It didn't — the label still says it's not established for that.)
• ❌ "HRT is an anti-aging treatment." (No.)
• ❌ "Compounded hormones are the same as FDA-approved ones." (Different category — more below.)

Which HRT products got updated labels first?

The FDA's first batch covered six products, one or more from each main category of menopause hormone therapy. As of the FDA's February 12, 2026 update, those products were Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. More are coming — the FDA said 29 drug companies submitted proposed label changes — so this is a rolling update, not a one-day switch.

Here's the first batch, with the category each falls in and a direct link to the real FDA label so you can verify it yourself.

If your product isn't on this list yet, it doesn't mean anything is wrong — it just means its updated label may not have posted. Always check your own product's current label before making a decision.

How do I check whether my specific HRT label was updated?

Start with the FDA's official "Menopausal Hormone Therapies with Updated Prescribing Information" page, then open the current label for your exact medication, dose, and route. If your product isn't listed yet, that doesn't automatically mean it's unsafe or unchanged — it means you should read the current label rather than trust a headline.

1. Go to the FDA's updated prescribing information page and look for your product by name.
2. Open the label (it's a PDF) and check the top. If the only thing in the boxed warning is the endometrial-cancer statement, the update has been applied.
3. Look at the "Recent Major Changes" note near the top — it spells out what was removed and when (you'll see a 2/2026 date on the updated ones).
4. If your product isn't there, search Drugs@FDA for the latest label, and ask your pharmacist or prescriber whether your specific product's labeling has changed yet.

This is why we keep a "Last verified" date at the top of this page and re-check the FDA list regularly.

Does the change apply to vaginal estrogen, patches, pills, and creams the same way?

No — the route matters a lot. Low-dose vaginal estrogen is "local" therapy that mostly works in one area. Patches, gels, and pills are "systemic" therapy that circulate through your whole body. The FDA's first batch included products from both groups, but the risk conversation is not identical across them.

The simplest way to think about it: how much hormone reaches your bloodstream changes how much the old systemic risks apply. Low-dose vaginal estrogen has long been the product clinicians most wanted freed from the heavy warning — for example, the FDA-approved Estring ring releases only about 7.5 micrograms of estradiol a day, and its own label notes that roughly 8% of that is absorbed into the body. That's a fraction of a systemic dose. Learn more in our vaginal estrogen guide.

The takeaway: one headline ("FDA removes HRT warning") sits on top of products that work very differently. Knowing which kind you have or want is step one.

Does this apply to compounded or "bioidentical" hormones?

Not in the same way. The FDA's change updated the labels of FDA-approved menopause products. Compounded hormones — custom-mixed by a pharmacy for one patient — are not FDA-approved finished drugs, so they were never carrying the FDA boxed warning to begin with. Removing a warning from approved products doesn't change a compounded product's status.

Quick definition: compounded hormones are mixed by a pharmacy for an individual, often sold as "bioidentical" creams, pellets, or troches. FDA-approved products go through the agency's review for safety, effectiveness, and consistent dosing.

Compounded hormones didn't "lose" an FDA black box warning, because they were never FDA-approved products with that label in the first place.

For years, some sellers leaned on a quiet contrast — "our compounded hormones don't have that scary black box warning." It sounded like a safety advantage. It never really was. The absence of the warning was a regulatory difference (these products skip FDA approval), not proof they were safer. And now that the warning is gone from FDA-approved products too, even that talking point doesn't separate them anymore.

Major medical groups — including the American College of Obstetricians and Gynecologists (ACOG) — recommend FDA-approved products over compounded ones when an approved option exists, partly because compounded products can vary in dose and quality and lack large safety studies. The FDA itself notes that compounded drugs are not FDA-approved, and the agency does not review their safety, effectiveness, or quality before they're sold.

The honest bottom line for telehealth: plenty of legitimate online programs prescribe FDA-approved hormones; others provide compounded products. Neither is automatically a scam. But "bioidentical" is a marketing word, not an FDA approval — and some products described as having "FDA-approved ingredients" are still compounded and not FDA-approved as a finished medicine. You deserve to know which one you're getting before you start.

Does any of this apply to testosterone (TRT)?

No. This change covers menopausal hormone therapy in the estrogen and progestogen categories — combination, estrogen-alone, progestogen-alone, and vaginal estrogen products. It does not change the rules for testosterone replacement therapy (TRT). Testosterone is a Schedule III controlled substance in the U.S. with its own separate labeling, and it still requires a prescription and proper medical supervision. If you searched expecting TRT news, this isn't it — the black box change doesn't touch testosterone.

Why was the black box warning there in the first place?

It came from a landmark study called the Women's Health Initiative (WHI). When early results were released in 2002, they suggested certain hormone therapies raised the risk of breast cancer, heart problems, blood clots, and possibly dementia. The FDA responded by adding the boxed warning in 2003, and hormone-therapy use fell sharply in the years that followed.

For two decades, that warning shaped how women and doctors saw HRT. A lot of people simply avoided it, even for miserable hot flashes or bone-loss risk.

What changed since then

Researchers kept studying the data, especially for younger women who started therapy closer to menopause — a group the original headlines didn't separate out well. The risk picture looked very different for them. Harvard Health reports that a 2025 analysis published in the journal Stroke on August 21, 2025 looked at nearly 57,000 postmenopausal women, part of a broader body of evidence that the old warning was too sweeping for the people most likely to seek treatment. The FDA's July 2025 expert panel and labeling review drew on long-term WHI follow-up analyses, a literature review, prescription-use data, and public input — and that review is what led to the change.

Why did the FDA decide the old warning was too broad?

Because one warning was being applied to very different products and very different patients. The old box treated a low-dose vaginal cream and a daily systemic pill as if they carried the same risk, and it didn't clearly account for a woman's age or how recently she'd gone through menopause. The FDA's view is that the warning's bluntness scared off women who could have safely benefited.

A few specific problems the agency and specialists pointed to:

• It didn't separate local from systemic. Low-dose vaginal estrogen barely reaches the bloodstream, yet it carried the same heavy warning as whole-body therapy.
• It didn't account for timing. Starting near menopause and starting 15 years later are different risk situations. The new labels add the "before 60 or within 10 years" framing.
• It scared off good candidates. The FDA framed the goal as letting women and doctors make decisions based on data, not fear — about giving women accurate information rather than an overblown warning.

A fair word about the caution

This wasn't unanimous cheering, and we won't pretend it was. Specialists broadly supported freeing low-dose vaginal estrogen from the box, but several urged more caution about the broader systemic messaging — worried that "the warning is gone" could be heard by the public as "there's no risk," especially around heart and brain claims. The Menopause Society's own statement makes that point: it backed the change while stressing that systemic estrogen still carries risks that need an individual conversation. That caution is exactly why this page keeps stressing the difference between removed from the box and no longer a risk. The label change makes an honest conversation easier. It doesn't replace one.

What to ask your doctor or online provider after the FDA change

Bring the update to your appointment — but use it as a starting point, not a self-diagnosis. A good conversation should cover your symptoms, your age, how long since your last period, whether you have a uterus, your cancer/clot/heart history, whether you'd use local or systemic therapy, and whether the medicine is FDA-approved or compounded.

Your clinician checklist

Print this or screenshot it:

1. What symptoms am I treating — hot flashes, night sweats, sleep, vaginal dryness, painful sex, urinary symptoms, bone-loss risk?
2. Am I under 60, or within 10 years of menopause?
3. Do I still have a uterus? If so, do I need a progestogen with systemic estrogen?
4. Should I consider local vaginal estrogen, systemic therapy, or both?
5. Is what you're prescribing FDA-approved or compounded?
6. Given my history (breast cancer, clots, stroke, heart, liver, any unexplained bleeding), what are my specific risks?
7. How will we choose the dose and route, and how often will we reassess?
8. What symptoms should make me stop and call you?

If you're looking at an online (telehealth) provider

The 2026 change makes provider transparency more important, not less. Before you start with any online HRT service, here's what a trustworthy one should answer clearly.

To make the FDA-approved vs. compounded difference concrete, here's what two popular menopause telehealth services say about their own medications. Provider-stated and verified June 5, 2026 — confirm current details on each provider's site before deciding.

Read that table the way it's meant: if you specifically want FDA-approved hormone therapy — the kind this whole page is about — a provider like Midi fits that goal. If you want a personalized, compounded formula and understand it isn't an FDA-approved product, Winona is upfront that its treatments are compounded. Different goals, different fit. The right answer is the one that matches what you want and what your clinician recommends.

The HRT Index may earn a commission from some provider links above; it never changes our FDA-status facts or safety statements.

What if you have a breast cancer history, blood clots, or unexplained bleeding?

Don't treat the 2026 label change as personal clearance if your history is complicated. People with a history of breast cancer or another hormone-sensitive cancer, blood clots, stroke, heart attack, active liver disease, or any unexplained vaginal bleeding need a direct conversation with a clinician — often a specialist — before starting HRT. The removal of a broad warning doesn't change your specific risks.

• Breast cancer history. Systemic HRT is usually a more complicated discussion for breast cancer survivors. In some cases, low-dose vaginal estrogen may be considered with oncology-informed guidance — but that's a doctor's call, made with your records in front of them, not a website's.
• Blood clots, stroke, or heart history. Route and timing matter here (for some people, a patch or gel may differ from a pill), and so does your full risk profile. This is a conversation, not a checkbox.
• Unexplained vaginal bleeding. This should be evaluated before any HRT decision, full stop.

If you're in any of these groups, the most useful thing we can do is be straight with you: this is exactly the situation where a quiz can't and shouldn't route you to a product. Take the questions above to a clinician who knows your history.

FDA black box warning HRT 2026: myths vs. facts

The update corrects an overly broad warning — it doesn't make HRT a wellness supplement. It also doesn't prove HRT prevents dementia, reverse aging, or make compounded hormones equal to FDA-approved ones. Here's a quick myth check.

How we verified this

We built this page from primary regulatory sources first, then specialist medical groups, and we read an actual updated drug label rather than relying on news summaries. Here's exactly what we checked.

• The FDA's February 12, 2026 announcement approving updated labels for the first six menopause hormone therapy products, and that the boxed-warning statements on cardiovascular disease, breast cancer, and probable dementia were removed.
• The FDA's updated prescribing information page listing Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva as the first products updated (current as of 2/12/2026).
• The actual updated Cenestin label (revised 2/2026) — confirming the boxed warning now covers only endometrial cancer, that the cardiovascular risks remain in Contraindications and Warnings & Precautions, that breast cancer remains in Contraindications and Malignant Neoplasms, and that the probable-dementia information was moved out of the box and Warnings & Precautions but still appears in Geriatric Use and Clinical Studies.
• That the endometrial-cancer boxed warning remains for systemic estrogen-alone products in women with a uterus.
• The timing guidance (starting before 60 or within 10 years of menopause) now reflected in systemic-product labeling.
• Provider-stated medication types, checked June 5, 2026: Midi Health states it prescribes FDA-approved bioidentical hormones; Winona states its 503A-compounded treatments are not FDA-approved.

What we re-check on a schedule: the FDA product list (monthly until the rollout settles, then quarterly), any new label updates beyond the first six, changes to FDA wording, and provider medication types whenever we reference a provider. The "Last verified" date at the top reflects the most recent check.

We're The HRT Index, an independent comparison resource for HRT telehealth providers. We may earn a commission if you choose certain partner providers through our links — but that never changes our medical statements, FDA-status facts, or safety cautions. If we removed every link on this page, the information would be exactly the same.

Frequently asked questions

Did the FDA remove the black box warning on HRT in 2026?

Yes, partly. In February 2026 the FDA approved updated labels for the first six menopause hormone therapy products, removing the boxed warnings about cardiovascular disease, breast cancer, and probable dementia. A boxed warning about endometrial (uterine) cancer remains for systemic estrogen-alone products in women with a uterus.

What HRT warning still remains?

The boxed warning about endometrial cancer remains for systemic estrogen-alone products in women who still have a uterus. Clinicians often pair systemic estrogen with a progestogen to help protect the uterine lining.

Does the FDA warning change mean HRT is safe for everyone?

No. The label change does not make HRT appropriate for everyone. Risk still depends on age, time since menopause, route, dose, uterus status, health history, and whether the medication is FDA-approved or compounded.

Does the change apply to vaginal estrogen?

Yes — the first batch included a low-dose vaginal estrogen product (Estring), and specialists especially supported removing the broad warning from low-dose vaginal estrogen, since very little of it reaches the bloodstream.

Does it apply to compounded or "bioidentical" hormones?

Not in the same way. The change updated FDA-approved product labels. Compounded hormones are not FDA-approved finished drugs — even when made with FDA-approved ingredients — so they were not carrying the FDA boxed warning to begin with.

Why does having a uterus matter?

If you have a uterus and use systemic estrogen, protecting the uterine lining is a key part of the safety conversation, because the endometrial-cancer warning remains for systemic estrogen-alone therapy. A progestogen is the usual protection.

Is HRT now recommended to prevent dementia or heart disease?

No. The dementia warning was moved out of the box, but the label still states the drug is not established for preventing dementia. HRT decisions are based on symptoms and individual risk, not prevention claims.

Does this affect testosterone or TRT?

No. The change covers menopausal hormone therapy in the estrogen and progestogen categories only. Testosterone is a Schedule III controlled substance with separate rules and still requires a prescription and medical supervision.

What if my doctor still mentions the old black box warning?

That's fine — bring the 2026 update and ask how it changes the risk-benefit picture for your specific situation. The label change is meant to make that conversation more accurate, not to end it.

When did the change take effect?

The FDA announced it on November 10, 2025, and approved the first updated labels on February 12, 2026. More products are being updated on a rolling basis.

Sources

• FDA — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (Feb 12, 2026)
• FDA — Menopausal Hormone Therapies with Updated Prescribing Information (product list, current as of 2/12/2026)
• FDA — HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (Nov 10, 2025)
• FDA — Cenestin updated prescribing information (rev. 2/2026)
• FDA — Human Drug Compounding: Questions and Answers
• American Cancer Society — What to Know About Hormone Replacement Therapy (HRT) and Cancer Risk
• Harvard Health — FDA removes menopause hormone therapy black box warnings
• The Menopause Society — statement on the FDA hormone therapy announcement